This Project may benefit participants for whom no standard-of-care option is available by providing treating oncologists with hypothesis-generating drug sensitivity data that may help inform next-line treatment decisions. If AI-identified predictive biomarkers are validated in vivo, results from this Project also may inform future clinical trials to determine whether using already-approved drugs in combination can effectively treat subpopulations of patients with unmet needs. Ultimately, this Project will benefit all individuals who will be diagnosed with cancer in their lifetime by advancing science in both functional precision oncology and AI-enabled predictive medicine.
All donations received by SOTERIA for the purposes of the clinical cancer research study will be placed into a restricted fund to be devoted to the purposes of and for the sole benefit of this Project’s mission.